SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-062912
Filing Date
2023-11-13
Accepted
2023-11-13 16:05:24
Documents
13
Period of Report
2023-11-13
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ubx-20231113.htm   iXBRL 8-K 47659
2 EX-99.1 ubx-ex99_1.htm EX-99.1 237969
  Complete submission text file 0000950170-23-062912.txt   417703

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ubx-20231113.xsd EX-101.SCH 2489
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ubx-20231113_pre.xml EX-101.PRE 11051
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ubx-20231113_lab.xml EX-101.LAB 14950
7 EXTRACTED XBRL INSTANCE DOCUMENT ubx-20231113_htm.xml XML 4716
Mailing Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 285 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 416-1192
Unity Biotechnology, Inc. (Filer) CIK: 0001463361 (see all company filings)

IRS No.: 264726035 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38470 | Film No.: 231398558
SIC: 2834 Pharmaceutical Preparations